{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T14:51:45Z","timestamp":1777042305652,"version":"3.51.4"},"reference-count":84,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background and purpose: Approximately 50% of patients with metastatic melanoma harbor mutations in the BRAF gene, making them eligible for targeted therapy (TT). However, treatment options become limited once resistance develops. The role of radiotherapy (RT) in this context remains uncertain, and concerns exist regarding toxicity when RT is delivered concurrently with TT.Patient\/material and methods: This retrospective study included metastatic melanoma patients treated with RT after experiencing disease progressing on TT between 2015 and 2023. Patients were grouped by subsequent systemic therapy: RT-STOP (discontinued TT), RT-TT (continued TT), and RT-ICI (switched to immune checkpoint inhibitors (ICI)). Study endpoints were progression-free survival (PFS), overall survival (OS), efficacy, and toxicity.Results: Sixty-three patients were analyzed. Median PFS and OS were 1.9 and 3.1 months. The median OS in RT-STOP, RT-TT, and RT-ICI was 1.7, 4.7, and 3.0 months, while the 1-year OS rate was 4.9, 7.6, and 33.4%, respectively (p = 0.001). RT was well tolerated, with no grade \u22653 adverse events observed and 50.9% of patients derived a local benefit.Interpretation: In advanced melanoma patients with disease progression on TT, RT was safe and provided a local effect. Although survival outcomes remained suboptimal, continuation of TT beyond progression or transition to ICI following RT was associated with improved OS compared with discontinuation of TT. These results support the role of RT as a safe bridging modality, suggest benefit from treatment beyond progression with TT, and warrant confirmation in prospective trials.<\/jats:p>","DOI":"10.2340\/ao.v65.45437","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T13:01:24Z","timestamp":1777035684000},"page":"344-354","source":"Crossref","is-referenced-by-count":0,"title":["The role of radiotherapy in patients with advanced melanoma failing targeted therapy"],"prefix":"10.2340","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1882-6103","authenticated-orcid":false,"given":"Ellen","family":"Heurlin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Gr\u00f6deberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0735-4771","authenticated-orcid":false,"given":"Hildur","family":"Helgadottir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"152627","doi-asserted-by":"crossref","unstructured":"Ottaviano M, Giunta EF, Tortora M, Curvietto M, Attademo L, Bosso D, et al. BRAF gene and melanoma: back to the future. Int J Mol Sci. 2021;22(7):3474.","DOI":"10.3390\/ijms22073474"},{"key":"152628","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/ijms22073474","DOI":"10.3390\/ijms22073474"},{"key":"152629","doi-asserted-by":"crossref","unstructured":"Bauer J, Buttner P, Murali R, Okamoto I, Kolaitis NA, Landi MT, et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res. 2011;24(2):345\u201351.","DOI":"10.1111\/j.1755-148X.2011.00837.x"},{"key":"152630","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1755-148X.2011.00837.x","DOI":"10.1111\/j.1755-148X.2011.00837.x"},{"key":"152631","doi-asserted-by":"crossref","unstructured":"Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507\u201316.","DOI":"10.1056\/NEJMoa1103782"},{"key":"152632","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1103782","DOI":"10.1056\/NEJMoa1103782"},{"key":"152633","doi-asserted-by":"crossref","unstructured":"Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107\u201314.","DOI":"10.1056\/NEJMoa1203421"},{"key":"152634","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1203421","DOI":"10.1056\/NEJMoa1203421"},{"key":"152635","doi-asserted-by":"crossref","unstructured":"Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877\u201388.","DOI":"10.1056\/NEJMoa1406037"},{"key":"152636","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1406037","DOI":"10.1056\/NEJMoa1406037"},{"key":"152637","doi-asserted-by":"crossref","unstructured":"Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30\u20139.","DOI":"10.1056\/NEJMoa1412690"},{"key":"152638","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1412690","DOI":"10.1056\/NEJMoa1412690"},{"key":"152639","doi-asserted-by":"crossref","unstructured":"Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867\u201376.","DOI":"10.1056\/NEJMoa1408868"},{"key":"152640","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1408868","DOI":"10.1056\/NEJMoa1408868"},{"key":"152641","doi-asserted-by":"crossref","unstructured":"Schadendorf D, Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, et al. COLUMBUS 7-year update: a randomized, open-\u00adlabel, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E\/K-mutant melanoma. Eur J Cancer. 2024;204:114073.","DOI":"10.1016\/j.ejca.2024.114073"},{"key":"152642","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114073","DOI":"10.1016\/j.ejca.2024.114073"},{"key":"152643","doi-asserted-by":"crossref","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381(7):626\u201336.","DOI":"10.1056\/NEJMoa1904059"},{"key":"152644","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1904059","DOI":"10.1056\/NEJMoa1904059"},{"key":"152645","doi-asserted-by":"crossref","unstructured":"Ascierto PA, McArthur GA, Dreno B, Atkinson V, Liszkay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248\u201360.","DOI":"10.1016\/S1470-2045(16)30122-X"},{"key":"152646","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S1470-2045(16)30122-X","DOI":"10.1016\/S1470-2045(16)30122-X"},{"key":"152647","doi-asserted-by":"crossref","unstructured":"Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023;41(2):186\u201397.","DOI":"10.1200\/JCO.22.01763"},{"key":"152648","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.22.01763","DOI":"10.1200\/JCO.22.01763"},{"key":"152649","doi-asserted-by":"crossref","unstructured":"Ascierto PA, Casula M, Bulgarelli J, Pisano M, Piccinini C, Piccin L, et al. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. Nat Commun. 2024;15(1):146.","DOI":"10.1038\/s41467-023-44475-6"},{"key":"152650","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41467-023-44475-6","DOI":"10.1038\/s41467-023-44475-6"},{"key":"152651","doi-asserted-by":"crossref","unstructured":"Priantti JN, Vilbert M, Madeira T, Moraes FCA, Hein ECK, Saeed A, et al. Efficacy and safety of rechallenge with BRAF\/MEK inhibitors in advanced melanoma patients: a systematic review and meta-analysis. Cancers (Basel). 2023;15(15):3754.","DOI":"10.3390\/cancers15153754"},{"key":"152652","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/cancers15153754","DOI":"10.3390\/cancers15153754"},{"key":"152653","doi-asserted-by":"crossref","unstructured":"Ribas A, Daud A, Pavlick AC, Gonzalez R, Lewis KD, Hamid O, et al. Extended 5-year follow-up results of a phase Ib study (BRIM7) of vemurafenib and cobimetinib in BRAF-mutant melanoma. Clin Cancer Res. 2020;26(1):46\u201353.","DOI":"10.1158\/1078-0432.CCR-18-4180"},{"key":"152654","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-4180","DOI":"10.1158\/1078-0432.CCR-18-4180"},{"key":"152655","doi-asserted-by":"crossref","unstructured":"Ascierto PA, Mandala M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, et al. Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-\u00adlabel phase II trial. J Clin Oncol. 2023;41(2):212\u201321.","DOI":"10.1200\/JCO.21.02961"},{"key":"152656","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.21.02961","DOI":"10.1200\/JCO.21.02961"},{"key":"152657","doi-asserted-by":"crossref","unstructured":"Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(10):1315\u201327.","DOI":"10.1016\/S1470-2045(18)30497-2"},{"key":"152658","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S1470-2045(18)30497-2","DOI":"10.1016\/S1470-2045(18)30497-2"},{"key":"152659","doi-asserted-by":"crossref","unstructured":"Hecht M, Zimmer L, Loquai C, Weishaupt C, Gutzmer R, Schuster B, et al. Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. Ann Oncol. 2015;26(6):1238\u201344.","DOI":"10.1093\/annonc\/mdv139"},{"key":"152660","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/annonc\/mdv139","DOI":"10.1093\/annonc\/mdv139"},{"key":"152661","doi-asserted-by":"crossref","unstructured":"Peuvrel L, Ruellan AL, Thillays F, Quereux G, Brocard A, Saint-Jean M, et al. Severe radiotherapy-induced extracutaneous toxicity under vemurafenib. Eur J Dermatol. 2013;23(6):879\u201381.","DOI":"10.1684\/ejd.2013.2193"},{"key":"152662","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1684\/ejd.2013.2193","DOI":"10.1684\/ejd.2013.2193"},{"key":"152663","doi-asserted-by":"crossref","unstructured":"Boussemart L, Boivin C, Claveau J, Tao YG, Tomasic G, Routier E, et al. Vemurafenib and radiosensitization. JAMA Dermatol. 2013;149(7):855\u20137.","DOI":"10.1001\/jamadermatol.2013.4200"},{"key":"152664","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2013.4200","DOI":"10.1001\/jamadermatol.2013.4200"},{"key":"152665","doi-asserted-by":"crossref","unstructured":"Satzger I, Degen A, Asper H, Kapp A, Hauschild A, Gutzmer R. Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy. J Clin Oncol. 2013;31(13):e220\u20132.","DOI":"10.1200\/JCO.2012.44.4265"},{"key":"152666","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.2012.44.4265","DOI":"10.1200\/JCO.2012.44.4265"},{"key":"152667","doi-asserted-by":"crossref","unstructured":"Palmer JD, Prasad RN, Fabian D, Wei L, Yildiz VO, Tan Y, et al. Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases. Radiother Oncol. 2022;170:21\u20136.","DOI":"10.1016\/j.radonc.2022.03.016"},{"key":"152668","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.radonc.2022.03.016","DOI":"10.1016\/j.radonc.2022.03.016"},{"key":"152669","doi-asserted-by":"crossref","unstructured":"Peuvrel L, Dreno B. Dermatological toxicity associated with targeted therapies in cancer: optimal management. Am J Clin Dermatol. 2014;15(5):425\u201344.","DOI":"10.1007\/s40257-014-0088-2"},{"key":"152670","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40257-014-0088-2","DOI":"10.1007\/s40257-014-0088-2"},{"key":"152671","doi-asserted-by":"crossref","unstructured":"Schick U, Kyula J, Barker H, Patel R, Zaidi S, Gregory C, et al. Trametinib radiosensitises RAS- and BRAF-mutated melanoma by perturbing cell cycle and inducing senescence. Radiother Oncol. 2015;117(2):364\u201375.","DOI":"10.1016\/j.radonc.2015.06.026"},{"key":"152672","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.radonc.2015.06.026","DOI":"10.1016\/j.radonc.2015.06.026"},{"key":"152673","doi-asserted-by":"crossref","unstructured":"M\u00e1rquez-Rodas I, Avil\u00e9s-Izquierdo JA, Parra V, \u00c1lvarez-Gonz\u00e1lez A, Borrego P, Fern\u00e1ndez-Garc\u00eda P, et al. Exclusion criteria vs reality: dual BRAF\/MEK inhibition and radiotherapy in a patient with melanoma metastatic to the brain and ECOG 3. Tumori. 2016;102(Suppl. 2):5000408.","DOI":"10.5301\/tj.5000408"},{"key":"152674","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.5301\/tj.5000408","DOI":"10.5301\/tj.5000408"},{"key":"152675","doi-asserted-by":"crossref","unstructured":"Wang W, Smith JL, Carlino MS, Burmeister B, Pinkham MB, Fogarty GB, et al. Phase I\/II trial of concurrent extracranial palliative radiation therapy with dabrafenib and trametinib in metastatic BRAF V600E\/K mutation-positive cutaneous melanoma. Clin Transl Radiat Oncol. 2021;30:95\u20139.","DOI":"10.1016\/j.ctro.2021.08.006"},{"key":"152676","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ctro.2021.08.006","DOI":"10.1016\/j.ctro.2021.08.006"},{"key":"152677","doi-asserted-by":"crossref","unstructured":"Ziegler JS, Kroeze S, Hilbers ML, Imhof L, Guckenberger M, Levesque MP, et al. Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis. Melanoma Res. 2020;30(6):552\u201361.","DOI":"10.1097\/CMR.0000000000000682"},{"key":"152678","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/CMR.0000000000000682","DOI":"10.1097\/CMR.0000000000000682"},{"key":"152679","doi-asserted-by":"crossref","unstructured":"Rossi E, Schinzari G, Cellini F, Balducci M, Pasqualoni M, Maiorano BA, et al. Dabrafenib-trametinib and radiotherapy for oligoprogressive BRAF mutant advanced melanoma. Biomedicines. 2023;11(2):394.","DOI":"10.3390\/biomedicines11020394"},{"key":"152680","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/biomedicines11020394","DOI":"10.3390\/biomedicines11020394"},{"key":"152681","doi-asserted-by":"crossref","unstructured":"van Aken ESM, Devnani B, Castelo-Branco L, De Ruysscher D, Martins-Branco D, Marijnen CAM, et al. ESMO-ESTRO framework for assessing the interactions and safety of combining radiotherapy with targeted cancer therapies or immunotherapy. Radiother Oncol. 2025;208:110910.","DOI":"10.1016\/j.radonc.2025.110910"},{"key":"152682","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110910","DOI":"10.1016\/j.radonc.2025.110910"},{"key":"152683","doi-asserted-by":"crossref","unstructured":"Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157\u201366.","DOI":"10.1016\/j.radonc.2020.04.003"},{"key":"152684","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.radonc.2020.04.003","DOI":"10.1016\/j.radonc.2020.04.003"},{"key":"152685","doi-asserted-by":"crossref","unstructured":"Van Not OJ, van den Eertwegh AJM, Haanen JB, van Rijn RS, Aarts MJB, van den Berkmortel F, et al. BRAF\/MEK inhibitor rechallenge in advanced melanoma patients. Cancer. 2024;130(9):1673\u201383.","DOI":"10.1002\/cncr.35178"},{"key":"152686","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/cncr.35178","DOI":"10.1002\/cncr.35178"},{"key":"152687","doi-asserted-by":"crossref","unstructured":"Schreuer M, Jansen Y, Planken S, Chevolet I, Seremet T, Kruse V, et al. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF(V600)-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. Lancet Oncol. 2017;18(4):464\u201372.","DOI":"10.1016\/S1470-2045(17)30171-7"},{"key":"152688","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S1470-2045(17)30171-7","DOI":"10.1016\/S1470-2045(17)30171-7"},{"key":"152689","doi-asserted-by":"crossref","unstructured":"Puzanov I, Amaravadi RK, McArthur GA, Flaherty KT, Chapman PB, Sosman JA, et al. Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: patterns of disease progression and clinical management of limited progression. Eur J Cancer. 2015;51(11):1435\u201343.","DOI":"10.1016\/j.ejca.2015.04.010"},{"key":"152690","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejca.2015.04.010","DOI":"10.1016\/j.ejca.2015.04.010"},{"key":"152691","doi-asserted-by":"crossref","unstructured":"Backlund E, Grozman V, Egyhazi Brage S, Lewensohn R, Lindberg K, Helgadottir H. Radiotherapy with or without immunotherapy in metastatic melanoma: efficacy and tolerability. Acta Oncol. 2023;62(12):1921\u201330.","DOI":"10.1080\/0284186X.2023.2280766"},{"key":"152692","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/0284186X.2023.2280766","DOI":"10.1080\/0284186X.2023.2280766"},{"key":"152693","doi-asserted-by":"crossref","unstructured":"Sambade MJ, Peters EC, Thomas NE, Kaufmann WK, Kimple RJ, Shields JM. Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol. 2011;98(3):394\u20139.","DOI":"10.1016\/j.radonc.2010.12.017"},{"key":"152694","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.radonc.2010.12.017","DOI":"10.1016\/j.radonc.2010.12.017"},{"key":"152695","doi-asserted-by":"crossref","unstructured":"Ly D, Bagshaw HP, Anker CJ, Tward JD, Grossmann KF, Jensen RL, et al. Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment. J Neurosurg. 2015;123(2):395\u2013401.","DOI":"10.3171\/2014.9.JNS141425"},{"key":"152696","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3171\/2014.9.JNS141425","DOI":"10.3171\/2014.9.JNS141425"},{"key":"152697","doi-asserted-by":"crossref","unstructured":"Patel KR, Chowdhary M, Switchenko JM, Kudchadkar R, Lawson DH, Cassidy RJ, et al. BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis. Melanoma Res. 2016;26(4):387\u201394.","DOI":"10.1097\/CMR.0000000000000268"},{"key":"152698","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/CMR.0000000000000268","DOI":"10.1097\/CMR.0000000000000268"},{"key":"152699","doi-asserted-by":"crossref","unstructured":"Marquez-Rodas I, Alvarez A, Arance A, Valduvieco I, Berciano-Guerrero MA, Delgado R, et al. Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN\/GEM1802 phase II study). Neuro Oncol. 2024;26(11):2074\u201383.","DOI":"10.1093\/neuonc\/noae116"},{"key":"152700","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/neuonc\/noae116","DOI":"10.1093\/neuonc\/noae116"},{"key":"152701","doi-asserted-by":"crossref","unstructured":"van Opijnen MP, Dirven L, Coremans IEM, Taphoorn MJB, Kapiteijn EHW. The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: a systematic review. Int J Cancer. 2020;146(6):1479\u201389.","DOI":"10.1002\/ijc.32696"},{"key":"152702","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/ijc.32696","DOI":"10.1002\/ijc.32696"},{"key":"152703","doi-asserted-by":"crossref","unstructured":"Koelblinger P, Thuerigen O, Dummer R. Development of encorafenib for BRAF-mutated advanced melanoma. Curr Opin Oncol. 2018;30(2):125\u201333.","DOI":"10.1097\/CCO.0000000000000426"},{"key":"152704","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/CCO.0000000000000426","DOI":"10.1097\/CCO.0000000000000426"},{"key":"152705","doi-asserted-by":"crossref","unstructured":"Yilmaz M, Celik U, Hascicek S. Radiation recall dermatitis with dabrafenib and trametinib: a case report. World J Clin Cases. 2020;8(3):522\u20136.","DOI":"10.12998\/wjcc.v8.i3.522"},{"key":"152706","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.12998\/wjcc.v8.i3.522","DOI":"10.12998\/wjcc.v8.i3.522"},{"key":"152707","doi-asserted-by":"crossref","unstructured":"Anker CJ, Grossmann KF, Atkins MB, Suneja G, Tarhini AA, Kirkwood JM. Avoiding severe toxicity from combined BRAF inhibitor and radiation treatment: consensus guidelines from the Eastern Cooperative Oncology Group (ECOG). Int J Radiat Oncol Biol Phys. 2016;95(2):632\u201346.","DOI":"10.1016\/j.ijrobp.2016.01.038"},{"key":"152708","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ijrobp.2016.01.038","DOI":"10.1016\/j.ijrobp.2016.01.038"},{"key":"152709","doi-asserted-by":"crossref","unstructured":"Rogers SJ, Puric E, Eberle B, Datta NR, Bodis SB. Radiotherapy for melanoma: more than DNA damage. Dermatol Res Pract. 2019;2019:9435389.","DOI":"10.1155\/2019\/9435389"},{"key":"152710","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1155\/2019\/9435389","DOI":"10.1155\/2019\/9435389"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/45437\/53657","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/45437\/53657","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T13:02:06Z","timestamp":1777035726000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/45437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":84,"URL":"https:\/\/doi.org\/10.2340\/ao.v65.45437","relation":{},"ISSN":["1651-226X"],"issn-type":[{"value":"1651-226X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]}}}